HC Wainwright Issues Negative Forecast for GENB Earnings

Generate Biomedicines Inc (NASDAQ:GENB) – Analysts at HC Wainwright cut their Q2 2026 EPS estimates for Generate Biomedicines in a research report issued on Friday, May 8th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.51) per share for the quarter, down from their prior estimate of ($0.48). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. HC Wainwright also issued estimates for Generate Biomedicines’ Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.54) EPS, FY2026 earnings at ($2.11) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.50) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.51) EPS and FY2027 earnings at ($2.09) EPS.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

GENB has been the topic of a number of other research reports. Piper Sandler started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective on the stock. Zacks Research raised shares of Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Guggenheim started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective on the stock. Morgan Stanley started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, The Goldman Sachs Group began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Generate Biomedicines Stock Performance

Shares of GENB opened at $14.37 on Tuesday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.89. The firm has a 50 day moving average of $12.68.

Key Generate Biomedicines News

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $25 price target on Generate Biomedicines, signaling continued upside confidence despite the forecast tweaks. Generate Biomedicines stock page
• Positive Sentiment: The analyst raised Q3 2026 EPS estimates to ($0.52) from ($0.54) and improved Q4 2026 estimates to ($0.54) from ($0.56), suggesting a slightly better operating outlook in parts of 2026. Generate Biomedicines stock page
• Neutral Sentiment: The stock also has support from its current price structure, opening near $14.37 versus a 52-week range of $11.00 to $15.89, which keeps investors focused on whether bullish analyst targets can be justified. Generate Biomedicines stock page
• Negative Sentiment: HC Wainwright cut estimates for Q2 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026, and FY2027, reflecting a somewhat softer earnings outlook and likely limiting further upside. Generate Biomedicines stock page
• Negative Sentiment: The company recently reported a Q1 earnings miss, posting ($1.07) EPS versus expectations of ($0.48), which may still be weighing on sentiment. Generate Biomedicines stock page

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.